Verve Therapeutics (VERV) Reports Q1 Loss, Tops Revenue Estimates

Verve Therapeutics (VERV) came out with a quarterly loss of $0.35 per share versus the Zacks Consensus Estimate of a loss of$ 0.71. This compares to loss of $0.59 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 50.70%. A quarter ago, it was expected that this biotechnology firm would post a loss of$ 0.72 per share when it actually produced a loss of $0.58, delivering a surprise of 19.44%.Over the last four quarters, the compan ...